Grufity logoGrufity logo
StocksFundsSearch FilingsAPI

Bristol-Myers Squibb Co Stock Research

BMY

59.08USD+0.30(+0.51%)Market Closed
Watchlist

Market Summary

USD59.08+0.30
Market Closed
0.51%

BMY Alerts

  • 1 major insider sales recently.
  • Big jump in Earnings (Y/Y)

BMY Stock Price

BMY RSI Chart

BMY Valuation

Market Cap

150.1B

Price/Earnings (Trailing)

23.72

Price/Sales (Trailing)

3.25

EV/EBITDA

7.27

Price/Free Cashflow

12.56

BMY Price/Sales (Trailing)

BMY Profitability

EBT Margin

19.19%

Return on Equity

22.97%

Return on Assets

7.75%

Free Cashflow Yield

7.96%

BMY Fundamentals

BMY Revenue

Revenue (TTM)

45.2B

Revenue Y/Y

-5.56%

Revenue Q/Q

-0.98%

BMY Earnings

Earnings (TTM)

8.0B

Earnings Y/Y

45.88%

Earnings Q/Q

-8.36%

Price Action

52 Week Range

58.3381.44
(Low)(High)

Last 7 days

-0.7%

Last 30 days

-4.5%

Last 90 days

-9.2%

Trailing 12 Months

-14.3%

BMY Financial Health

Current Ratio

1.42

BMY Investor Care

Diluted EPS (TTM)

3.76

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales

Latest Insider Trading transactions for BMY

Filter Transactions
Datesorted ascendingNameBuy/Sell$ ValueAvg. Price# SharesTitle
2023-08-24
Powell Ann
sold
-1,101,640
61.25
-17,986
evp, chief human resources
2023-08-03
Plenge Robert M
sold
-44,754
61.14
-732
evp, chief research officer
2023-07-01
Weese Michelle
acquired
-
-
1,885
evp, corporate affairs
2023-07-01
Hirawat Samit
sold (taxes)
-306,129
63.95
-4,787
evp,chief med.offr.,drug dev.
2023-07-01
Hirawat Samit
acquired
-
-
9,357
evp,chief med.offr.,drug dev.
2023-07-01
Weese Michelle
sold (taxes)
-43,613
63.95
-682
evp, corporate affairs
2023-06-03
Lenkowsky Adam
sold (taxes)
-36,178
65.66
-551
evp, chief commercial officer
2023-06-03
Lenkowsky Adam
acquired
-
-
1,077
evp, chief commercial officer
2023-05-03
VESSEY RUPERT
sold
-3,378,820
67.06
-50,385
evp & president, research
2023-05-02
Greenlees Sharon
acquired
-
-
1,017
svp & controller

1–10 of 50

Which funds bought or sold BMY recently?

View All Details
Datesorted ascendingFund NameType% Chg$ Change$ Held% Portfolio
2023-09-19
BIRMINGHAM CAPITAL MANAGEMENT CO INC/AL
added
0.35
-228,812
2,858,120
1.20%
2023-09-18
WASHINGTON CAPITAL MANAGEMENT, INC
unchanged
-
-27,872
332,540
0.28%
2023-09-14
IMS Capital Management
added
0.25
-31,184
384,929
0.21%
2023-09-14
Proquility Private Wealth Partners, LLC
added
0.16
-97,698
1,190,360
0.47%
2023-09-12
DCM Advisors, LLC
sold off
-100
-213,891
-
-%
2023-09-12
Farther Finance Advisors, LLC
added
325
936,805
1,256,810
0.28%
2023-09-11
Dechtman Wealth Management, LLC
new
-
640,987
640,987
0.19%
2023-09-08
TUCKER ASSET MANAGEMENT LLC
reduced
-6.8
-1,000
6,139
-%
2023-09-07
ST GERMAIN D J CO INC
new
-
1,456,140
1,456,140
0.08%
2023-09-07
JAG CAPITAL MANAGEMENT, LLC
reduced
-16.66
-74,653
248,580
0.03%

1–10 of 48

Latest Funds Activity

Are funds buying BMY calls or puts?
Calls
Puts
No. of funds holding Calls - Puts
Net Call Options
No. of funds that own BMY
No. of Funds

Schedule 13G FIlings of Bristol-Myers Squibb

Date FiledName of FilerPercent of ClassNo. of SharesForm Type
Feb 09, 2023
vanguard group inc
9.54%
202,927,620
SC 13G/A
Feb 07, 2023
blackrock inc.
8.1%
172,720,377
SC 13G/A
Feb 09, 2022
vanguard group inc
9.00%
199,834,483
SC 13G/A
Feb 01, 2022
blackrock inc.
7.6%
169,226,706
SC 13G/A
Feb 10, 2021
vanguard group inc
8.82%
199,340,458
SC 13G/A
Jan 29, 2021
blackrock inc.
7.6%
172,464,804
SC 13G/A
Feb 12, 2020
vanguard group inc
8.32%
194,860,154
SC 13G/A
Feb 05, 2020
blackrock inc.
7.3%
171,343,446
SC 13G/A
Jan 28, 2020
wellington management group llp
3.57%
83,470,877
SC 13G/A

Recent SEC filings of Bristol-Myers Squibb

View All Filings
Date Filed Form Type Document
Aug 28, 2023
4
Insider Trading
Aug 24, 2023
144
Notice of Insider Sale Intent
Aug 10, 2023
8-K
Current Report
Aug 07, 2023
4
Insider Trading
Aug 03, 2023
144
Notice of Insider Sale Intent
Jul 27, 2023
10-Q
Quarterly Report
Jul 27, 2023
8-K
Current Report
Jul 05, 2023
4
Insider Trading
Jul 05, 2023
3
Insider Trading
Jul 05, 2023
4
Insider Trading

Peers (Alternatives to Bristol-Myers Squibb)

View All Peers In Detail
NameMkt Capsorted ascendingRevenuePrice %, 1MReturns, 1YP/EP/SRev 1-YrInc 1-Yr
LARGE-CAP
495.0B
29.5B
-0.64% 86.07%
76.18
16.77
1.53% 14.16%
420.1B
97.8B
-2.63% 0.36%
32.18
4.3
2.29% -28.92%
272.8B
58.3B
-0.47% 27.98%
17.88
4.63
2.00% -81.24%
185.5B
77.9B
-10.83% -24.56%
8.64
2.38
-23.04% -26.74%
150.1B
45.2B
-4.49% -14.30%
23.72
3.25
-4.15% 20.34%
MID-CAP
6.5B
-
1.73% 596.48%
-74.02
4.1K
-86.94% 71.24%
4.4B
4.6B
-13.48% -15.45%
-65.31
0.95
6.60% 42.04%
SMALL-CAP
1.6B
627.1M
-7.75% -19.97%
-1.08
2.5
-0.20% -204.67%
1.5B
634.0M
-13.44% -19.42%
34.58
2.36
0.62% -24.59%
843.4M
244.3M
-2.42% 7.48%
4.28
3.45
-39.50% -4.99%
807.9M
109.5M
20.45% -29.10%
-5.63
7.38
-2.66% -32.13%
482.6M
31.2M
-9.55% -49.48%
-4.58
15.49
407.54% -26.47%
422.3M
453.3M
90.89% -73.90%
-0.34
0.93
-16.04% 55.90%
258.3M
54.6M
-16.41% -43.89%
-2.85
4.73
9.39% -179.16%
-
2.2B
- -
-
-
-22.39% 63.59%

Bristol-Myers Squibb News

MarketWatch
Bristol Myers Squibb Co. stock outperforms competitors on strong trading day.
MarketWatch,
7 hours ago
Best Stocks
Bristol-Myers Squibb
Investing.com UK

Returns for BMY

Cumulative Returns on BMY

5.1%


10-Year Cumulative Returns

3.4%


7-Year Cumulative Returns

1.6%


5-Year Cumulative Returns

3.1%


3-Year Cumulative Returns

Risks for BMY

What is the probability of a big loss on BMY?

45%


Probability that Bristol-Myers Squibb stock will be more than 20% underwater in next one year

1.9%


Probability that Bristol-Myers Squibb stock will be more than 30% underwater in next one year.

0%


Probability that Bristol-Myers Squibb stock will be more than 40% underwater in next one year.
*Calculated based on probability distribution of losses observed in actual data in the last 5 years.

How does BMY drawdown profile look like?

Y-axis is the maximum loss one would have experienced if Bristol-Myers Squibb was unfortunately bought at previous high price.

Drawdowns

Financials for Bristol-Myers Squibb

Income Statement (Last 12 Months)
(In Millions)
Income Statement (Last 12 Months)
(In Millions)
(*) denotes actual numbers (not divided by Millions)
Description(%) Q/Q2023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q42018Q32018Q2
Revenue-1.4%45,18745,84846,15946,73847,14446,96046,38545,46844,38442,81042,51839,39534,86231,00626,14524,17323,85723,28822,56122,03721,600
Gross Profit-----------30,74528,04024,21921,09018,06716,81916,79416,384---
Costs and Expenses-1.5%36,49037,05238,44639,02639,48439,70538,28749,67948,49546,84749,38935,94432,31928,31421,17017,56416,43017,12016,59316,87617,423
  S&GA Expenses1.9%7,8927,7457,8147,9027,7607,8557,6908,0577,9757,7217,6616,6746,0235,4714,8714,4734,5224,5774,5514,5314,590
  R&D Expenses-0.7%9,5079,5709,5099,51710,07910,23610,19510,3329,8519,89510,0489,4908,3697,1726,1485,4185,3206,4306,3326,8907,171
EBITDA-100.0%-18,91717,98919,44619,54619,35520,2848,2008,2288,1345,10912,7919,3997,1597,1357,4918,3037,0326,8056,0235,062
EBITDA Margin-100.0%-0.41*0.39*0.42*0.42*0.41*0.44*0.18*0.19*0.19*0.12*0.32*0.27*0.23*0.27*0.31*0.35*0.30*0.30*0.27*0.23*
Earnings Before Taxes-1.1%8,6978,7967,7137,7127,6607,2558,098-4,211-4,111-4,037-6,8713,4512,5432,6924,9756,6097,4276,1685,9685,1614,177
EBT Margin-100.0%-0.19*0.17*0.17*0.16*0.15*0.17*-0.09*-0.09*-0.09*-0.16*0.09*0.07*0.09*0.19*0.27*0.31*0.26*0.26*0.23*0.19*
Net Income8.9%7,9637,3116,3276,6776,6176,2516,994-5,405-5,079-6,219-9,015-44.00-5639543,4395,6556,2035,1444,9201,432376
Net Income Margin-100.0%-0.16*0.14*0.14*0.14*0.13*0.15*-0.12*-0.11*-0.15*-0.21*0.00*-0.02*0.03*0.13*0.23*0.26*0.22*0.22*0.06*0.02*
Free Cashflow-100.0%-11,08111,94812,72514,28115,14215,23414,88411,68713,24213,29911,84212,4099,8967,3747,5836,2725,2394,9893,7134,109
Balance Sheet
(In Millions)
Balance Sheet
(In Millions)
(*) denotes actual numbers (not divided by Millions)
Description(%) Q/Q2023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q42018Q32018Q2
Assets-0.8%93,48994,28196,82098,196100,357103,034109,314110,893110,797112,435118,481125,536128,076129,285129,94457,43355,16334,83434,98633,73432,641
  Current Assets3.6%28,07427,08627,27326,79630,18630,12133,26231,44329,16127,11130,19234,27734,34331,85329,35440,19137,71617,09317,71614,86913,874
    Cash Equivalents-6.9%8,3728,9959,1237,73410,96012,57914,31613,87911,39711,32114,97319,86020,36216,24612,82030,48928,4047,3356,9115,4084,999
  Inventory-9.3%2,3642,6052,3392,0742,1422,1042,0952,1632,1371,9532,0741,9492,3842,8364,2931,1921,3081,2831,1951,2821,242
  Net PPE1.2%6,3556,2796,2556,0355,9706,0476,0495,8685,7955,7635,8865,7405,7776,1126,2524,8304,8494,9855,0275,0925,080
  Goodwill0.0%21,16321,16221,14921,11220,44620,50020,50220,51920,52920,52420,54720,51720,57822,45222,4886,5136,5336,5366,5386,6866,683
Liabilities-1.5%61,45962,39565,70265,46267,69671,38973,30873,60973,92374,76280,59975,30678,91679,30878,24639,67939,01219,51720,85919,98420,223
  Current Liabilities5.6%20,15019,08521,89018,93020,91522,82121,86821,46018,99117,33019,08020,46423,42119,23218,30410,4899,7118,84110,6549,6949,878
  Long Term Debt-----------50,33644,61446,10646,10546,15024,39024,4335,635---
    LT Debt, Non Current-1.2%34,65635,07835,05636,96637,10737,45039,60539,67742,50344,50548,33641,36441,85342,84443,38724,39024,4335,6355,6465,6875,671
Shareholder's Equity0.5%31,97331,82431,06132,67132,60031,58035,94637,21336,80837,60537,82250,23049,16049,97751,59817,75416,15115,31714,03113,75012,418
  Retained Earnings3.3%27,44926,56825,50324,67524,21723,94823,82022,62522,16822,20421,28132,41431,56532,67134,47436,55535,87035,10934,06533,29232,044
  Additional Paid-In Capital0.4%45,29945,14045,16544,95644,37543,75644,36144,29244,06443,85244,32544,43544,44443,25443,7092,2062,1502,1032,0812,0291,966
Minority Interest-8.1%57.0062.0057.0063.0061.0065.0060.0071.0066.0068.0060.0072.0066.0066.0010010610299.0096.00110101
Cashflow (Last 12 Months)
(In Millions)
Cashflow (Last 12 Months)
(In Millions)
(*) denotes actual numbers (not divided by Millions)
Description(%) Q/Q2023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q42018Q32018Q2
Cashflow From Operations-3.1%11,85012,22413,06613,81715,39616,19516,20715,50512,50613,93914,05212,87813,16710,7578,2109,5848,3077,2817,0664,6285,062
  Share Based Compensation4.4%493472457471498539583621664720779892763598441210216219221218206
Cashflow From Investing-2.9%-1,407-1,367-1,062-1,874-769-300-538-12,751-11,988-11,612-10,859-11,226-10,522-10,363-9,913804166-897-2,000481770
Cashflow From Financing9.4%-13,012-14,359-16,962-17,683-14,920-14,582-16,224-8,774-9,581-7,392-1,151-12,311-10,6658,5967,62114,72014,941-4,342-3,535-4,309-4,295
  Dividend Payments1.0%4,6924,6454,6344,5884,5244,4734,3964,3184,2444,1664,0753,7223,3773,0272,6792,6642,6462,6292,6132,5992,586
  Buy Backs26.9%4,2723,3678,0018,4528,2769,5126,2875,0014,4763,2401,5467,0817,3817,3817,300300-153320569789

BMY Income Statement

2023-06-30
CONSOLIDATED STATEMENTS OF EARNINGS - USD ($)
$ in Millions
3 Months Ended6 Months Ended
Jun. 30, 2023
Jun. 30, 2022
Jun. 30, 2023
Jun. 30, 2022
Total revenues$ 11,226$ 11,887$ 22,563$ 23,535
Cost of products sold[1]2,8762,7205,4425,191
Marketing, selling and administrative1,9341,7873,6963,618
Research and development2,2582,3214,5794,581
Acquired IPRD158400233733
Amortization of acquired intangible assets2,2572,4174,5134,834
Other (income)/expense, net(116)284(529)933
Total Expenses9,3679,92917,93419,890
Earnings before income taxes1,8591,9584,6293,645
Income tax (benefit)/provision(218)529285933
Net earnings2,0771,4294,3442,712
Noncontrolling interest48913
Net earnings attributable to BMS$ 2,073$ 1,421$ 4,335$ 2,699
Earnings per common share:    
Basic (usd per share)$ 0.99$ 0.67$ 2.07$ 1.26
Diluted (usd per share)$ 0.99$ 0.66$ 2.06$ 1.25
Net product sales    
Total revenues$ 10,917$ 11,485$ 21,965$ 22,793
Alliance and other revenues    
Total revenues$ 309$ 402$ 598$ 742
[1]Excludes amortization of acquired intangible assets

BMY Balance Sheet

2023-06-30
CONSOLIDATED BALANCE SHEETS (UNAUDITED) - USD ($)
$ in Millions
Jun. 30, 2023
Dec. 31, 2022
Current assets:  
Cash and cash equivalents$ 8,372$ 9,123
Marketable debt securities358130
Receivables10,1129,886
Inventories2,3642,339
Other current assets6,8685,795
Total Current assets28,07427,273
Property, plant and equipment6,3556,255
Goodwill21,16321,149
Other intangible assets31,30335,859
Deferred income taxes1,5721,344
Other non-current assets5,0224,940
Total Assets93,48996,820
Current liabilities:  
Short-term debt obligations3,0204,264
Accounts payable3,0693,040
Other current liabilities14,06114,586
Total Current liabilities20,15021,890
Deferred income taxes7512,166
Long-term debt34,65635,056
Other non-current liabilities5,9026,590
Total Liabilities61,45965,702
Commitments and Contingencies
BMS Shareholders’ equity:  
Preferred stock00
Common stock292292
Capital in excess of par value of stock45,29945,165
Accumulated other comprehensive loss(1,387)(1,281)
Retained earnings27,44925,503
Less cost of treasury stock(39,680)(38,618)
Total BMS Shareholders’ equity31,97331,061
Noncontrolling interest5757
Total Equity32,03031,118
Total Liabilities and Equity$ 93,489$ 96,820
Giovanni Caforio
32200
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 diseases. The company's products include Revlimid, an oral immunomodulatory drug for the treatment of multiple myeloma; Eliquis, an oral inhibitor for reduction in risk of stroke/systemic embolism in NVAF, and for the treatment of DVT/PE; Opdivo for anti-cancer indications; Pomalyst/Imnovid indicated for patients with multiple myeloma; and Orencia for adult patients with active RA and psoriatic arthritis. It also provides Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia; Yervoy for the treatment of patients with unresectable or metastatic melanoma; Abraxane, a protein-bound chemotherapy product; Reblozyl for the treatment of anemia in adult patients with beta thalassemia; and Empliciti for the treatment of multiple myeloma. In addition, the company offers Zeposia to treat relapsing forms of multiple sclerosis; Breyanzi, a CD19-directed genetically modified autologous T cell immunotherapy for the treatment of adult patients with relapsed or refractory large B-cell lymphoma; Inrebic, an oral kinase inhibitor indicated for the treatment of adult patients with myelofibrosis; and Onureg for the treatment of adult patients with AML. It sells products to wholesalers, distributors, pharmacies, retailers, hospitals, clinics, and government agencies. The company was formerly known as Bristol-Myers Company. The company was founded in 1887 and is headquartered in New York, New York.